ZA202000375B - Compounds for the prevention and treatment of medical disorders and uses thereof - Google Patents
Compounds for the prevention and treatment of medical disorders and uses thereofInfo
- Publication number
- ZA202000375B ZA202000375B ZA2020/00375A ZA202000375A ZA202000375B ZA 202000375 B ZA202000375 B ZA 202000375B ZA 2020/00375 A ZA2020/00375 A ZA 2020/00375A ZA 202000375 A ZA202000375 A ZA 202000375A ZA 202000375 B ZA202000375 B ZA 202000375B
- Authority
- ZA
- South Africa
- Prior art keywords
- compounds
- treatment
- prevention
- medical disorders
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540860P | 2017-08-03 | 2017-08-03 | |
| PCT/US2018/045175 WO2019028357A1 (en) | 2017-08-03 | 2018-08-03 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202000375B true ZA202000375B (en) | 2025-04-30 |
Family
ID=65233534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/00375A ZA202000375B (en) | 2017-08-03 | 2020-01-20 | Compounds for the prevention and treatment of medical disorders and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11583530B2 (enExample) |
| EP (1) | EP3661502A4 (enExample) |
| JP (1) | JP7498108B2 (enExample) |
| KR (1) | KR102692840B1 (enExample) |
| CN (1) | CN111032039B (enExample) |
| AU (1) | AU2018309085B2 (enExample) |
| BR (1) | BR112020001698A2 (enExample) |
| CA (1) | CA3069745A1 (enExample) |
| IL (1) | IL272097B2 (enExample) |
| MX (1) | MX2020001256A (enExample) |
| WO (1) | WO2019028357A1 (enExample) |
| ZA (1) | ZA202000375B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| WO2019028357A1 (en) | 2017-08-03 | 2019-02-07 | Galectin Sciences, Llc | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CN113476442A (zh) * | 2021-07-28 | 2021-10-08 | 上海交通大学医学院附属第九人民医院 | 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用 |
| GB2631507A (en) * | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| GB2631509A (en) * | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT377586B (de) * | 1981-06-30 | 1985-04-10 | Erba Farmitalia | Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen |
| ES524262A0 (es) * | 1982-08-05 | 1984-11-16 | Erba Farmitalia | "procedimiento para preparar derivados de quinazolina" |
| SE0100172D0 (sv) * | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| WO2002060392A2 (en) | 2001-01-31 | 2002-08-08 | Synaptic Pharmaceutical Corporation | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| SK9562003A3 (en) | 2001-01-31 | 2004-04-06 | Synaptic Pharma Corp | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| NZ538029A (en) * | 2002-07-09 | 2006-08-31 | Actelion Pharmaceuticals Ltd | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
| US7220775B2 (en) | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
| DE10304141B4 (de) * | 2003-02-03 | 2006-03-09 | Hf Arzneimittelforschung Gmbh | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
| US9221840B2 (en) * | 2011-05-17 | 2015-12-29 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule CFTR correctors |
| RU2606635C2 (ru) * | 2011-07-13 | 2017-01-10 | Сантен Фармасьютикал Ко., Лтд. | Новое соединение, проявляющее ингибиторную активность в отношении parp |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| CN113621005B (zh) * | 2015-01-30 | 2025-07-04 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| CN105272986A (zh) * | 2015-06-15 | 2016-01-27 | 厦门医学高等专科学校 | 一种可抑制乙酰胆碱酯酶活性的化合物或其制备方法和应用 |
| CN106220631B (zh) * | 2016-07-26 | 2019-02-05 | 中山大学 | 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用 |
| WO2019028357A1 (en) | 2017-08-03 | 2019-02-07 | Galectin Sciences, Llc | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF |
-
2018
- 2018-08-03 WO PCT/US2018/045175 patent/WO2019028357A1/en not_active Ceased
- 2018-08-03 JP JP2020505233A patent/JP7498108B2/ja active Active
- 2018-08-03 BR BR112020001698-5A patent/BR112020001698A2/pt not_active Application Discontinuation
- 2018-08-03 KR KR1020207005279A patent/KR102692840B1/ko active Active
- 2018-08-03 CA CA3069745A patent/CA3069745A1/en active Pending
- 2018-08-03 EP EP18841404.9A patent/EP3661502A4/en active Pending
- 2018-08-03 AU AU2018309085A patent/AU2018309085B2/en active Active
- 2018-08-03 IL IL272097A patent/IL272097B2/en unknown
- 2018-08-03 US US16/629,373 patent/US11583530B2/en active Active
- 2018-08-03 CN CN201880050555.3A patent/CN111032039B/zh active Active
- 2018-08-03 MX MX2020001256A patent/MX2020001256A/es unknown
-
2020
- 2020-01-20 ZA ZA2020/00375A patent/ZA202000375B/en unknown
-
2022
- 2022-07-08 US US17/861,023 patent/US12377102B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200147088A1 (en) | 2020-05-14 |
| EP3661502A1 (en) | 2020-06-10 |
| CN111032039B (zh) | 2024-03-26 |
| EP3661502A4 (en) | 2020-12-02 |
| IL272097B2 (en) | 2024-06-01 |
| CA3069745A1 (en) | 2019-02-07 |
| AU2018309085B2 (en) | 2022-12-08 |
| AU2018309085A1 (en) | 2020-02-06 |
| BR112020001698A2 (pt) | 2020-07-21 |
| US12377102B2 (en) | 2025-08-05 |
| KR20200035982A (ko) | 2020-04-06 |
| US11583530B2 (en) | 2023-02-21 |
| IL272097A (en) | 2020-03-31 |
| IL272097B1 (en) | 2024-02-01 |
| JP2020529988A (ja) | 2020-10-15 |
| MX2020001256A (es) | 2020-08-17 |
| US20230116370A1 (en) | 2023-04-13 |
| CN111032039A (zh) | 2020-04-17 |
| KR102692840B1 (ko) | 2024-08-07 |
| WO2019028357A1 (en) | 2019-02-07 |
| JP7498108B2 (ja) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2018006223A (es) | Moduladores de ror-gamma. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| PH12016502015A1 (en) | Anti-factor d antibody variants and uses thereof | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| MX376700B (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| WO2016109002A3 (en) | Methods and compositions for the treatment of radiation-related disorders | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
| PH12019500464A1 (en) | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |